Yuki Agarwala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuki Agarwala has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Abigail Colley
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication - Ann E. Sluder
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Boston, MA, United States
1 shared publication - Daiki Sugita
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
1 shared publication - Deniz Koku
Department of Surgery & Cancer, Imperial College London, London, UK
1 shared publication - Eric Ofori Aboagye
Department of Surgery and Cancer, Imperial College London, London, UK
1 shared publication - George Bushra Hanna
Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK
1 shared publication
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
New Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
Open AccessNew Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.
- Open Access
- 16 May 2026
- Published by Springer Nature in Metabolomics
- Vol. 22 (3) , 75
Measurement of immune cell-derived volatile organic compounds from ex vivo and in vitro cultures: a scoping review
Background: Volatile organic compounds (VOCs) originate from cellular metabolic activity and disease-related biochemical processes and are emerging as non-invasive biomarkers. Although immune cells undergo marked metabolic and functional reprogramming during activation and differentiation, their contribution to the cellular volatile metabolome remains poorly characterised. Aim of review: This scoping review aims to systematically map experimental studies reporting untargeted VOCs emitted from mammalian immune cell cultures, with particular emphasis on volatilomics workflows and confidence in metabolite identification. Key scientific concepts of review: A systematic literature search identified experimental studies analysing headspace VOCs from primary and immortalised immune cells. Data were extracted on cell models, stimulation conditions, headspace sampling strategies, analytical platforms and data processing workflows. Analytical quality and confidence in compound assignment were assessed using the Chemical Analysis Working Group–Metabolomics Standards Initiative (CAWG-MSI) criteria. Eleven studies met the inclusion criteria, employing a heterogeneous range of sampling and analytical approaches, including solid-phase microextraction, sorbent-based thermal desorption and secondary electrospray ionisation coupled to high-resolution mass spectrometry. Across studies, reported VOC profiles were able to distinguish immune cell type, activation state and external stimuli, supporting the biological plausibility of immune-derived volatilomic signatures. However, substantial methodological variability was evident. Only one study achieved CAWG-MSI level 1 identification, and most lacked key metadata, internal standards or validation procedures. Overall, immune cells appear to emit distinct VOC signatures linked to immunometabolic state, but current practices limit reproducibility, cross-study comparability and confident biological interpretation. This review identifies metabolomics-specific methodological priorities required to characterise immune-derived VOCs.
- 16 May 2026
- Published by Springer Nature in Metabolomics
- Vol. 22 (3) , 75
Open AccessMeasurement of immune cell-derived volatile organic compounds from ex vivo and in vitro cultures: a scoping review
Background: Volatile organic compounds (VOCs) originate from cellular metabolic activity and disease-related biochemical processes and are emerging as non-invasive biomarkers. Although immune cells undergo marked metabolic and functional reprogramming during activation and differentiation, their contribution to the cellular volatile metabolome remains poorly characterised. Aim of review: This scoping review aims to systematically map experimental studies reporting untargeted VOCs emitted from mammalian immune cell cultures, with particular emphasis on volatilomics workflows and confidence in metabolite identification. Key scientific concepts of review: A systematic literature search identified experimental studies analysing headspace VOCs from primary and immortalised immune cells. Data were extracted on cell models, stimulation conditions, headspace sampling strategies, analytical platforms and data processing workflows. Analytical quality and confidence in compound assignment were assessed using the Chemical Analysis Working Group–Metabolomics Standards Initiative (CAWG-MSI) criteria. Eleven studies met the inclusion criteria, employing a heterogeneous range of sampling and analytical approaches, including solid-phase microextraction, sorbent-based thermal desorption and secondary electrospray ionisation coupled to high-resolution mass spectrometry. Across studies, reported VOC profiles were able to distinguish immune cell type, activation state and external stimuli, supporting the biological plausibility of immune-derived volatilomic signatures. However, substantial methodological variability was evident. Only one study achieved CAWG-MSI level 1 identification, and most lacked key metadata, internal standards or validation procedures. Overall, immune cells appear to emit distinct VOC signatures linked to immunometabolic state, but current practices limit reproducibility, cross-study comparability and confident biological interpretation. This review identifies metabolomics-specific methodological priorities required to characterise immune-derived VOCs.
- Open Access
- 10 November 2025
- Published by Elsevier in Clinical Radiology
- Vol. 92, 107167
Radiomics of hepatopancreatobiliary cancer diagnosis, management, and future prospects
- 10 November 2025
- Published by Elsevier in Clinical Radiology
- Vol. 92, 107167
Open AccessRadiomics of hepatopancreatobiliary cancer diagnosis, management, and future prospects